Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monopar TherapeuticsMNPR +1.44%33 1-Year Share Buyback Ratio is -9.70 as of Jun. 2026. GuruFocus rates MNPR with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 1,106 Biotechnology companies, Monopar Therapeutics ranks better than 57.41% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Monopar Therapeutics's current 1-Year Share Buyback Ratio was -9.70%.
MNPR's 1-Year Share Buyback Ratio is ranked better than 57.41% of 1106
companies
in the Biotechnology industry
Industry Median: -14.6
vs MNPR: -9.70
Monopar Therapeutics (NAS:MNPR) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Monopar Therapeutics 1-Year Share Buyback Ratio Related Terms
MNPR vs PHAT, AURA, NVCT: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Monopar Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monopar Therapeutics 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Monopar Therapeutics's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -9.70 mean?
Monopar Therapeutics (MNPR) has a 1-Year Share Buyback Ratio of -9.70 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Monopar Therapeutics and its competitors. According to the industry distribution chart, Monopar Therapeutics ranks #471 out of 1106 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Monopar Therapeutics' 1-Year Share Buyback Ratio too high?
Monopar Therapeutics' current 1-Year Share Buyback Ratio is -9.70. Based on the distribution chart, Monopar Therapeutics ranks #471 out of 1106 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Monopar Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' 1-Year Share Buyback Ratio compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Monopar Therapeutics ranks #471 out of 1106 companies for 1-Year Share Buyback Ratio. This puts Monopar Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Monopar Therapeutics and its competitors. Monopar Therapeutics's current 1-Year Share Buyback Ratio is -9.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current 1-Year Share Buyback Ratio of -9.70. The current 1-Year Share Buyback Ratio is -9.70. Monopar Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current 1-Year Share Buyback Ratio is -9.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
33GF Score
Get the complete analysis for MNPR
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNPR has been successfully added to your 
